 |
 |
PharmaVOICE - February 2010 Opportunities in Oncology Development By Denise Myshko Advances in cancer research, knowledge, treatment options, and awareness have increased tremendously in the past 25 years. Rates of new diagnoses and deaths from all cancers have declined significantly for men and women overall and for most racial and ethnic populations in the United States, according to the National Cancer Institute. These decreases are driven largely by declines in rates of new cases and rates of death for the three most common cancers in men — lung, prostate, and colorectal — and for two of the three leading cancers in women — breast and colorectal. New diagnoses for all types of cancer combined in the United States decreased, on average, almost 1% per year from 1999 to 2006. Cancer deaths decreased 1.6% per year... Sidebar: Oncology Marketing: Stepping up the Science A Pipeline Check: Company Developments The Cancer Genome Atlas THOUGHT LEADERS Roberto J. Bitton, M.D. Medical Oncologist, Pg. Dip. Health Economics, Senior Project Leader, Operations & Proposal Development, Kendle, a global clinical research organization that provides the full range of early- to late-stage clinical development services for the world’s biopharmaceutical industry. For more information, visit kendle.com. David Chang, M.D. VP, Global Clinical Development, Hematology/Oncology, Amgen, a human therapeutics company in the biotechnology industry. For more information, visit amgen.com. Jens Oliver Funk, M.D. Senior VP and Global Head of Therapeutic Area Oncology, EMD Serono Inc., an affiliate of Merck KGaA, a biopharmaceutical company focused on growing its product portfolio in cancer, neurodegenerative diseases, and fertility. For more information, visit emdserono.com. Jamal Gasmi, M.D., Ph.D. VP and Global Oncology Therapeutic Area Group Leader, Icon Clinical Research, which specializes in the planning, management, execution, and analysis of Phase II to Phase IV clinical trials. For more information, visit iconplc.com. Richard Gaynor, M.D. VP of Oncology Product Development and Medical Affairs, Eli Lilly and Co., which is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. For more information, visit lilly.com. Stephen M. Kelsey, M.D. Executive VP, Chief Medical Officer, Oncology, Geron Corp., which is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. For more information, visit geron.com. Richard Nelson. VP, Clinical Research, PharmaNet Development Group Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. For more information, visit pharmanet.com. Alison O’Neill, M.D. VP, Medical Affairs, TransMolecular Inc., an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases. For more information, visit transmolecular.com. Andrea Perrone, M.D. VP, Clinical Operations, Medical Director, BioClinica Inc., which supports pharmaceutical innovation with imaging core lab, electronic data capture, interactive voice and Web response, and optimization solutions. For more information, visit bioclinica.com. Marco Romano. Chief Medical Officer and Head of the Oncology Therapeutic Area Team, Chiltern International Ltd., a global clinical contract research organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas. For more information, visit chiltern.com. Ronny K. Schnel. Executive Director, Business Development & Client Services, Criterium Inc., a global, full-service, and technology driven contract research organization that offers clinical research solutions for the biopharmaceutical, pharmaceutical, medical device, and CRO industries. For more information, visit criteriuminc.com. Nancy Simonian, M.D. Chief Medical Officer, Millennium: The Takeda Oncology Company, a biopharmaceutical company whose development and commercialization activities are focused in oncology. For more information, visit millennium.com. Steve Tregay, Ph.D. President and CEO, Forma Therapeutics, which unlocks intractable drug targets to create transformative small molecule cancer therapies. For more information, visit formatherapeutics.com. Jeff Weisberg, D.O., FACP. Senior Medical Director, i3 Research, a full-service, global CRO therapeutically focused on: central nervous system, oncology, respiratory and infectious diseases, endocrinology and metabolic diseases, and cardiology. For more information, visit i3global.com.
|
